- Home
- GNLX vs VERU Comparison
GNLX vs VERU Comparison
Compare GNLX & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- VERU
- Stock Information
- Founded
- GNLX 2001
- VERU 1971
- Country
- GNLX United States
- VERU United States
- Employees
- GNLX N/A
- VERU N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- GNLX Health Care
- VERU Health Care
- Exchange
- GNLX Nasdaq
- VERU Nasdaq
- Market Cap
- GNLX 103.6M
- VERU 107.2M
- IPO Year
- GNLX 2023
- VERU 1990
- Fundamental
- Price
- GNLX $2.27
- VERU $0.65
- Analyst Decision
- GNLX Strong Buy
- VERU Strong Buy
- Analyst Count
- GNLX 4
- VERU 4
- Target Price
- GNLX $18.25
- VERU $4.00
- AVG Volume (30 Days)
- GNLX 142.7K
- VERU 1.1M
- Earning Date
- GNLX 11-14-2024
- VERU 02-06-2025
- Dividend Yield
- GNLX N/A
- VERU N/A
- EPS Growth
- GNLX N/A
- VERU N/A
- EPS
- GNLX N/A
- VERU N/A
- Revenue
- GNLX $8,000.00
- VERU $16,886,419.00
- Revenue This Year
- GNLX N/A
- VERU N/A
- Revenue Next Year
- GNLX N/A
- VERU N/A
- P/E Ratio
- GNLX N/A
- VERU N/A
- Revenue Growth
- GNLX N/A
- VERU N/A
- 52 Week Low
- GNLX $1.60
- VERU $0.36
- 52 Week High
- GNLX $16.60
- VERU $1.92
- Technical
- Relative Strength Index (RSI)
- GNLX 38.68
- VERU 42.01
- Support Level
- GNLX $2.13
- VERU $0.60
- Resistance Level
- GNLX $2.80
- VERU $0.82
- Average True Range (ATR)
- GNLX 0.20
- VERU 0.07
- MACD
- GNLX -0.04
- VERU -0.01
- Stochastic Oscillator
- GNLX 14.21
- VERU 22.32
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.